Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term. We intend in our study to proof the hypothesis, whether it is possible to decrease NT-proBNP levels by intensified cardiac prevention care We aim those patients, who already have elevated levels, although no history of a cardiac disease. This decrease in NT-proBNP should be translated consequently in a decrease in cardiac events

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Collaborator: Roche Pharma AG
• Treatments: Bisoprolol; Telmisartan

Criteria

Inclusion Criteria:

• Age > 18 years

• Known Diabetes mellitus > 6 months

• Increased Nt-proBNP above 125pg/ml

• Given informed consent

Exclusion Criteria:

• Disease other than diabetes, with a life expectancy below 1 year

• patients who suffer from chronic infection or malignant disease

• Women in childbearing age without contraceptive

• History of cardiac disease

• systemic cortisone treatment

• patients who are on chronic or acute hemodialysis, ultra filtration or peritoneal dialysis